The $116.7M Bet on the Immune System's Secret Police Force
TRex Bio just went public with $117 million and Eli Lilly as its biggest shareholder, all to boost the immune system's own peacekeeping cells. The Treg therapy space is heating up fast, and the race to reinvent autoimmune treatment is officially on.
Your immune system has its own cops. White blood cells hunt down invaders, attack infections, and destroy abnormal cells. But like any police force, sometimes they go rogue. They start attacking healthy tissue instead, causing autoimmune diseases like lupus, eczema, and inflammatory bowel disease.
Turns out, your body already has internal affairs. They're called regulatory T cells, or Tregs, and their job is to keep the rest of the immune system in check. When Tregs fail, inflammation runs wild.
TRex Bio just raised $116.7 million in an IPO built entirely around boosting those internal affairs agents. And Eli Lilly is betting big that it works.
Lilly's Favorite Startup Goes Public
TRex Bio priced its IPO at $14 per share, selling roughly 8.3 million shares on Nasdaq under the ticker TRXB. The price landed at the bottom of its marketed range ($14 to $16), which means investors were interested but not exactly fighting over the last slice of pizza.
Still, raising nearly $117 million in a selective biotech IPO market is no small feat. J.P. Morgan and Evercore led the offering as joint book-running managers, and underwriters secured a 30-day option to buy up to 1.25 million additional shares.
The real headline, though, is who's already sitting at the table. Eli Lilly is TRex Bio's largest shareholder, with a stake that hovered around 23.9% heading into the IPO. Lilly has been backing TRex since its $59 million Series A in 2021, participated in every subsequent funding round, and signed a $55 million collaboration deal in January 2023. That kind of sustained commitment from a pharma giant worth hundreds of billions doesn't happen by accident.
What TRex Bio Actually Does
Most autoimmune drugs work like a volume knob: they turn down the entire immune system. That helps with the inflammation, but it also leaves patients more vulnerable to infections and cancer. It's the therapeutic equivalent of unplugging your smoke detector because the toast keeps burning.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
TRex Bio wants to do something fundamentally different. Instead of suppressing the whole system, the company is trying to amplify the body's natural peacekeepers (those Tregs we talked about). The idea is to restore balance rather than impose silence.
The twist that makes TRex Bio's approach interesting: Tregs don't behave the same way everywhere. A Treg in your skin acts differently from one in your gut. TRex Bio's platform maps these tissue-specific behaviors, then designs drugs that activate the right Tregs in the right place.
The Pipeline: Three Programs, Three Angles
TRex Bio's lead candidate is TRB-061, a drug that activates a receptor called TNFR2 to expand Tregs in inflamed tissues. Its first target? Moderate-to-severe atopic dermatitis (severe eczema, for the rest of us). This is the company's most advanced wholly owned program.
Behind it sits TRB-071, a CD30 agonist being developed for inflammatory bowel disease. This one is earlier stage, still working through the studies needed before it can enter human trials. Its mechanism is a two-for-one: it boosts tissue Tregs while also blocking inflammatory signaling pathways.
Then there's TRB-051, which is where Lilly enters the picture directly. This program is fully partnered with Lilly, meaning the pharma giant handles development and commercialization. Recent reports suggest it's advancing toward a Phase 2a study in lupus with skin involvement. Lilly paid $55 million upfront for the rights to this program, plus participation in TRex Bio's equity rounds. That's a lot of conviction for a company founded just eight years ago.
A Growing (and Crowded) Neighborhood
TRex Bio isn't the only company that noticed Tregs might be important. The regulatory T-cell space has gone from niche curiosity to legitimate therapeutic frontier over the past two years.
Sonoma Biotherapeutics is arguably the most visible competitor, running a Phase 1 trial of engineered Treg cell therapy in rheumatoid arthritis. Sonoma also locked down a partnership with Regeneron for ulcerative colitis and Crohn's disease, which validated the broader approach. Other names in the space include Quell, Kyverna, Abata Therapeutics, Regcell, and Tr1x, each pursuing slightly different angles on the same biological insight.
The key difference: most of these competitors are building cell therapies, where you extract a patient's cells, engineer them, and put them back. That's powerful but expensive and hard to manufacture at scale. TRex Bio is developing biologics (protein-based drugs), which are generally easier to scale and cheaper to produce. Think of it as the difference between a custom-tailored suit and a really well-fitting one off the rack. Both can look great; one is a lot easier to make for millions of people.
The IPO Market: Open, but Picky
Biotech IPOs in 2026 have rebounded from the brutal drought of 2024 and 2025, but investors aren't writing blank checks. The companies getting funded tend to share a few traits: clinical-stage assets, near-term catalysts, experienced leadership, and credible backers.
TRex Bio checks several of those boxes. CEO Johnston Erwin is a Lilly veteran. The Lilly partnership provides both financial backing and scientific credibility. And TRB-061 gives the company a clinical-stage lead program to point to.
Pricing at the bottom of the range, though, is a reminder that "open" doesn't mean "easy." Investors said yes, but with a discount. That's the 2026 IPO market in a nutshell: "yes, but prove it."
Why This Matters Beyond TRex Bio
The bigger story here isn't one company's IPO. It's the growing belief that autoimmune disease treatment is overdue for a paradigm shift.
For decades, the standard playbook has been broad immunosuppression: drugs like methotrexate, steroids, and TNF blockers that dampen the immune system across the board. They work, but with significant trade-offs. The next generation of autoimmune therapies, whether Treg-based biologics from TRex Bio or engineered cell therapies from Sonoma, aims to be more surgical.
If Treg-based approaches prove out in mid-stage trials over the next few years, the implications are enormous. Autoimmune diseases affect roughly 50 million Americans. A treatment that restores immune balance without compromising immune defense would be a genuine game-changer.
TRex Bio now has $116.7 million and a public currency to pursue that vision. Lilly is watching from the largest seat in the shareholder meeting. The science is compelling; the competition is heating up. Now comes the hard part: proving it works in patients.
4 min read
GSK Thinks It Can Build a Better Flu Shot With mRNA
GSK's mRNA flu vaccine just beat both standard and high-dose flu shots in a mid-stage trial of 971 adults. Now it's heading to Phase 3, putting GSK squarely in Moderna's rearview mirror in the race to reinvent the annual flu shot.
